Conditions: Asthma
Keywords: Sputum cell counts Neutrophils Severe Asthma ICS Inhaled corticosteroids
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7
Healthy volunteers: no

Brief summary:
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid therapy in patients with moderate to severe asthma with elevated sputum neutrophils.

Detailed description:

Arms:
arm 1: 12 day repeat dosing with placebo arm 2: 12 day repeat dosing treatment phase with 100mg GSK2190915.

Interventions: intervention 1: GSK2190195 100mg intervention 2: Placebo
Intervention descriptions: intervention 1: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. intervention 2: Placebo :

2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)

Protocol document: